Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621707 | 0.76 | GPR119 (0.37) | GPR119KDM4EMAPTTHRBMEN1 | |
| SCHEMBL3837667 | 0.64 | MEN1 (0.61) | GPR119KDM4EMEN1KMT2A | |
| SCHEMBL25389387 | 0.62 | MEN1 (0.68) | GPR119MEN1KMT2A | |
| SCHEMBL4711418 | 0.62 | HPGD (0.55) | GPR119MEN1KMT2A | |
| SCHEMBL7421811 | 0.62 | MEN1 (0.57) | GPR119KDM4EMEN1KMT2A | |
| SCHEMBL3012474 | 0.62 | JAK2 (0.62) | GPR119KDM4ETHRBMEN1KMT2A | |
| SCHEMBL16565369 | 0.61 | GPR119 (0.39) | GPR119 | |
| SCHEMBL19633473 | 0.61 | HPGD (0.54) | GPR119 | |
| SCHEMBL803527 | 0.61 | JAK2 (0.74) | GPR119KDM4ETHRBMEN1KMT2A | |
| SCHEMBL4773177 | 0.61 | RECQL (0.58) | GPR119KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GPR119 207/4885KDM4E 4532/4885MAPT 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.